Trial
NCT03153982
Ruxolitinib in Operable Head and Neck Cancer
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of California, San Francisco
Collaborators
Incyte Corporation
Condition
Head and Neck Squamous Cell Carcinoma
Intervention
Ruxolitinib
Why stopped
Low accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-10-30